Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
Susan Hutchinson, David W Dodick, Christina Treppendahl, Nathan L Bennett, Sung Yun Yu, Hua Guo, Joel M Trugman, Susan Hutchinson, David W Dodick, Christina Treppendahl, Nathan L Bennett, Sung Yun Yu, Hua Guo, Joel M Trugman
Abstract
Introduction: Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The efficacy and safety of ubrogepant were demonstrated in two pivotal phase 3, single-attack, randomized, placebo-controlled trials (ACHIEVE I and ACHIEVE II).
Methods: We conducted a post hoc analysis of pooled data from the ACHIEVE trials to evaluate the efficacy, safety, and tolerability of ubrogepant 50 mg (the only dose evaluated in both trials) versus placebo across a large population of participants with migraine. The coprimary efficacy outcomes were pain freedom and absence of the most bothersome migraine-associated symptom (including photophobia, phonophobia, and nausea) at 2 h post dose. Secondary outcomes included pain relief at 2 h post dose, sustained pain relief and pain freedom from 2 to 24 h, and absence of specific migraine-associated symptoms at 2 h post dose.
Results: A total of 2240 eligible participants were randomized to placebo (n = 1122) or ubrogepant 50 mg (n = 1118) in the ACHIEVE trials. Pain freedom at 2 h was reported in 13.0% of participants in the pooled placebo group and 20.5% in the pooled ubrogepant 50 mg group (odds ratio [OR] 1.72; 95% confidence interval [CI] 1.34, 2.22; P < 0.001). Absence of the most bothersome migraine-associated symptom at 2 h was reported by 27.6% in the pooled placebo group and by 38.7% in the pooled ubrogepant 50 mg group (OR 1.68; 95% CI 1.37, 2.05; P < 0.001). Adverse events (AEs) within 48 h after the initial or optional second dose were reported by 11.5 and 11.2% of participants in the pooled placebo and pooled ubrogepant 50 mg groups, respectively. The most common AE was nausea (1.8 and 1.9%, respectively). No serious AEs related to treatment or discontinuations due to AEs were reported.
Conclusion: These results further support the efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine.
Trial registration: ClinicalTrials.gov Identifiers: ACHIEVE I: NCT02828020; ACHIEVE II: NCT02867709.
Keywords: Calcitonin gene–related peptide; Gepant; Headache; Migraine; Ubrogepant.
Figures
References
- Silberstein SD. Migraine. Lancet. 2004;363(9406):381–91.
- Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754–762. doi: 10.1212/WNL.55.6.754.
- Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973–89.
- Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778–793. doi: 10.1111/head.12550.
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. doi: 10.1111/head.12499.
- Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007;47(4):475–479. doi: 10.1111/j.1526-4610.2007.00752.x.
- Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773–780. doi: 10.1111/j.1526-4610.2006.00437.x.
- Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278–289. doi: 10.1111/head.12198.
- Williams GS. Triptan use and discontinuation: results from the MAST study. Neurol Rev. 2018;26(8):30.
- Marcus SC, Shewale AR, Silberstein SD, et al. Triptan discontinuation and treatment patterns among migraine patients initiating triptan treatment in a US commercially insured population (S59.003) [abstract]. Neurology. 2019;92(15 Suppl).
- Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Silver Spring: US Food and Drug Administration; 2015. .
- Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300–1311. doi: 10.1111/head.12154.
- Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2017;57(10):1507–1521. doi: 10.1111/head.13179.
- Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–1168. doi: 10.1111/j.1526-4610.2008.01217.x.
- Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
- Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649. doi: 10.1016/j.ncl.2019.06.001.
- Allergan. Ubrelvy. Package insert. Madison: Allergan USA, Inc.; 2020.
- Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi: 10.1056/NEJMoa1813049.
- Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant versus placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898. doi: 10.1001/jama.2019.16711.
- Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials. ACHIEVE I and II Headache. 2020;60(4):686–700.
- Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
- Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141–152. doi: 10.1111/head.13682.
- GlaxoSmithKline. Imitrex. Package insert. Research Triangle Park: GlaxoSmithKline; 2017.
- Valeant Pharmaceuticals. Migranal. Package insert. Bridgewater: Valeant Pharmaceuticals North America; 2019.
- American Headache Society The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
- Dodick DW, Shewale AS, Lipton RB, et al. (eds). Operationalization of triptan labels to identify migraine patients with cardiovascular contraindications and warnings using real-world claims data [poster]. Annual Meeting for the American Headache Society; 4–7 June 2020; San Diego.
- Rubio-Beltran E, Chan KY, van den Bogaerdt A, et al. (eds) Characterization of the effects of the calcitonin gene-related peptide (CGRP) receptor antagonists, atogepant and ubrogepant, on isolated human coronary, cerebral, and middle meningeal arteries [abstract]. Annual Meeting of the American Academy of Neurology; 4–10 May 2019; Philadelphia.
- Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu S, et al. Safety of ubrogepant in participants with moderate to high cardiovascular risk [abstract P124] Headache. 2019;59(suppl 1):104–105.
- National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA. 2001;285(19):2486–97.
- Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, et al. Ubrogepant is effective for the acute treatment of migraine in patients with an insufficient response to triptans [abstract]. Neurology. 2019;92(15 Suppl):P3.10–024.
Source: PubMed